Muraglitazar

SKU: orb1705016

Description

Muraglitazar (BMS-298585) is a potent dual agonist of PPARα and PPARγ, with EC50 values of 320 nM and 110 nM, respectively. It has been investigated in preclinical research for the treatment of type 2 diabetes and dyslipidemia, demonstrating efficacy in both in vitro assays and in vivo animal models.

Research Area

Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 331741-94-7
• MW: 516.54
• Purity: 99.31% (May vary between batches)
• Formula: C₂₉H₂₈N₂O₇
• SMILES: C(COC1=CC=C(CN(C(OC2=CC=C(OC)C=C2)=O)CC(O)=O)C=C1)C=3N=C(OC3C)C4=CC=CC=C4
• Target: PPAR
• Solubility: 10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (6.39 mM);DMSO:128.8 mg/mL (249.35 mM)

Bioactivity

• Target IC50:
  PPARα (HEK293 cells):1.41 μM (EC50)|PPARγ:110 nM (EC50)|PPARγ:0.14 μM|PPARα:320 nM (EC50)|PPARα:0.42 μM|PPARγ (HEK293 cells):0.04 μM (EC50)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BMS298585, BMS-298585, BMS 298585, Pargluva, Muraglitazar, human PPARγ, hPPARα

Compound Identifiers

PubChem CID

206044